Additionally, in HCC, lysosomal protein transmembrane five and protein arginine N-methyltransferase 6 (PRMT6) were considered the critical contributors to sorafenib and lenvatinib resistance, separately (Pan et al., 2023; Li et al., 2024). This evidence concerns the gene PRMT6 and hepatocellular carcinoma.